IL177894A0 - Stabilised supersaturated solids of lipophilic drugs - Google Patents

Stabilised supersaturated solids of lipophilic drugs

Info

Publication number
IL177894A0
IL177894A0 IL177894A IL17789406A IL177894A0 IL 177894 A0 IL177894 A0 IL 177894A0 IL 177894 A IL177894 A IL 177894A IL 17789406 A IL17789406 A IL 17789406A IL 177894 A0 IL177894 A0 IL 177894A0
Authority
IL
Israel
Prior art keywords
lipophilic drugs
solids
stabilised
stabilised supersaturated
supersaturated solids
Prior art date
Application number
IL177894A
Other languages
English (en)
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL177894(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of IL177894A0 publication Critical patent/IL177894A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL177894A 2004-03-10 2006-09-05 Stabilised supersaturated solids of lipophilic drugs IL177894A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
IL177894A0 true IL177894A0 (en) 2006-12-31

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177894A IL177894A0 (en) 2004-03-10 2006-09-05 Stabilised supersaturated solids of lipophilic drugs

Country Status (32)

Country Link
US (1) US8715735B2 (enExample)
EP (2) EP2087883B1 (enExample)
JP (1) JP5006185B2 (enExample)
KR (1) KR101210695B1 (enExample)
CN (1) CN1984644B (enExample)
AR (1) AR048500A1 (enExample)
AT (1) ATE442131T1 (enExample)
AU (1) AU2005221403B8 (enExample)
BR (1) BRPI0507342A (enExample)
CA (1) CA2558582C (enExample)
CR (1) CR8630A (enExample)
DE (1) DE602005016551D1 (enExample)
DK (1) DK1765290T3 (enExample)
EA (1) EA012746B1 (enExample)
EC (1) ECSP066902A (enExample)
ES (2) ES2332229T3 (enExample)
GT (1) GT200500045A (enExample)
HR (1) HRP20090614T1 (enExample)
IL (1) IL177894A0 (enExample)
MY (1) MY142989A (enExample)
NO (1) NO20064473L (enExample)
NZ (1) NZ549793A (enExample)
PA (1) PA8626101A1 (enExample)
PE (1) PE20060016A1 (enExample)
PL (1) PL1765290T3 (enExample)
PT (1) PT1765290E (enExample)
RS (1) RS51076B (enExample)
SI (1) SI1765290T1 (enExample)
SV (1) SV2005002044A (enExample)
TW (1) TWI345986B (enExample)
UY (1) UY28803A1 (enExample)
WO (1) WO2005087199A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127609A1 (en) * 2007-04-11 2008-10-23 Mccarty John A Melatonin tablet and methods of preparation and use
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CA2612456C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Gel compositions for topical administration
WO2006138686A1 (en) * 2005-06-16 2006-12-28 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
LT2487163T (lt) 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
US20110097405A1 (en) * 2008-02-13 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
WO2009113522A1 (ja) * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
BRPI0911871A8 (pt) 2008-05-02 2018-03-06 Gilead Sciences Inc uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
EP2381946A4 (en) * 2008-10-10 2012-08-08 Teva Womens Health Inc METHOD FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN CASE RATED PROSTATE RAY PATIENTS WITH LOW-DOSED CYPROTERONE ACETATE
WO2010094623A1 (en) * 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9005608B2 (en) * 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3171871B1 (en) 2014-07-21 2024-10-23 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
US11013245B2 (en) * 2017-02-14 2021-05-25 Dsm Ip Assets B.V. Water dispersible formulations
US10806706B2 (en) * 2017-02-14 2020-10-20 Dsm Ip Assets B.V. Storage-stable formulations
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2022069437A (ja) * 2020-10-23 2022-05-11 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
ATE102022T1 (de) 1990-08-30 1994-03-15 Senju Pharma Co Zusammensetzung zur kontrollierten abgabe von medikamenten.
ATE118178T1 (de) * 1990-11-29 1995-02-15 Faulding F H & Co Ltd Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern.
DE4326240A1 (de) 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
EP1598069B1 (en) 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
BR0107683A (pt) 2000-01-18 2002-11-12 Schering Ag Drospirenona para terapia de reposição de hormÈnio
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CA2448825C (en) * 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
DK1558265T3 (da) 2002-11-05 2010-03-15 Bayer Schering Pharma Ag Anvendelse af dropspirenon til behandling af hypertension
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
WO2004073689A1 (en) 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion

Also Published As

Publication number Publication date
MY142989A (en) 2011-02-14
PL1765290T3 (pl) 2010-02-26
KR101210695B1 (ko) 2012-12-11
EP2087883B1 (en) 2012-07-25
SI1765290T1 (sl) 2010-01-29
KR20060132999A (ko) 2006-12-22
BRPI0507342A (pt) 2007-07-03
CN1984644B (zh) 2010-12-08
AR048500A1 (es) 2006-05-03
JP5006185B2 (ja) 2012-08-22
US8715735B2 (en) 2014-05-06
AU2005221403A1 (en) 2005-09-22
ECSP066902A (es) 2006-12-20
ATE442131T1 (de) 2009-09-15
HK1103660A1 (en) 2007-12-28
WO2005087199A2 (en) 2005-09-22
CA2558582C (en) 2013-07-16
JP2007528389A (ja) 2007-10-11
ES2332229T3 (es) 2010-01-29
DE602005016551D1 (de) 2009-10-22
TWI345986B (en) 2011-08-01
CN1984644A (zh) 2007-06-20
WO2005087199A8 (en) 2007-03-29
DK1765290T3 (da) 2009-11-02
RS51076B (sr) 2010-10-31
NZ549793A (en) 2010-06-25
WO2005087199A3 (en) 2009-01-15
PA8626101A1 (es) 2006-07-03
HRP20090614T1 (hr) 2009-12-31
GT200500045A (es) 2005-10-31
UY28803A1 (es) 2005-10-31
AU2005221403B8 (en) 2010-01-07
EP1765290B1 (en) 2009-09-09
EP1765290A2 (en) 2007-03-28
CA2558582A1 (en) 2005-09-22
PE20060016A1 (es) 2006-02-16
ES2390406T3 (es) 2012-11-12
TW200600116A (en) 2006-01-01
NO20064473L (no) 2006-10-10
EA012746B1 (ru) 2009-12-30
US20050207990A1 (en) 2005-09-22
SV2005002044A (es) 2005-11-04
EA200601588A1 (ru) 2007-02-27
AU2005221403B2 (en) 2009-12-10
PT1765290E (pt) 2009-11-23
EP2087883A1 (en) 2009-08-12
CR8630A (es) 2007-06-06

Similar Documents

Publication Publication Date Title
TWI345986B (en) Stabilised supersaturated solids of lipophilic drugs
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
IL206888A0 (en) Compound capable of binding s1p receptor and pharmaceutical use thereof
IL187387A0 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
IL174232A0 (en) Combinations of drugs for the treatment of neoplasms
EP1531844A4 (en) NOVEL PROLONGED RELEASE PHARMACEUTICAL COMPOUNDS FOR PREVENTING THE ABUSE CONSUMPTION OF CONTROLLED SUBSTANCES
IL182615A0 (en) Pharmaceutical compounds
GB0416728D0 (en) Medicinal use of receptor ligands
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
IL176932A0 (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
IL164438A0 (en) Sustaubed release of guaifenesin combination drugs
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
GB0424742D0 (en) Pharmaceutical compounds
GB0327742D0 (en) Novel uses of known drugs
IL176061A0 (en) Nitrooxyderivatives of antihypertensive drugs
GB0428554D0 (en) Pharmaceutical compounds
GB0328040D0 (en) Pharmaceutical uses of bisphosphonates
HU0200337D0 (en) Stabilised pharmaceutical composition
GB0327389D0 (en) Stabilised pharmaceutical compositions
GB0424016D0 (en) Medicinal use of receptor ligands
GB0414197D0 (en) Medicinal use of receptor ligands
GB0414196D0 (en) Medicinal use of receptor ligands
GB0425413D0 (en) Medicinal use of receptor ligands
GB0424015D0 (en) Medicinal use of receptor ligands
GB0424018D0 (en) Medicinal use of receptor ligands